Changeflow GovPing Healthcare & Life Sciences Anti-HER2 Antibodies and Methods of Use Thereof
Routine Rule Added Final

Anti-HER2 Antibodies and Methods of Use Thereof

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO published patent application US20260109781A1 for anti-HER2 antibodies on April 23, 2026, filed October 8, 2025 under application number 19352786. The application covers antibodies binding to subdomain II and/or subdomain IV of human HER2, including bispecific formats using a common light chain, for treating cancer and brain metastasis. Inventors include Abira Bandyopadhyay, Allisa Jayne Clemens, Do Jin Kim, Michelle E. Pizzo, Lu Shan, Richard Théolis Jr., and Raymond Ka Hang Tong.

“In one aspect, antibodies that bind to subdomain II of human HER2 are provided.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.

What changed

The USPTO published patent application US20260109781A1 covering anti-HER2 antibodies that bind to subdomain II and/or subdomain IV of human HER2 protein, including bispecific antibody formats using a common light chain polypeptide. The application also discloses methods of treating cancer and treating brain metastasis of cancer using these antibodies. The patent claims priority to application 19352786 and was published April 23, 2026.

Pharmaceutical and biotechnology companies developing HER2-targeted oncology therapies should monitor this application for potential freedom-to-operate considerations or licensing opportunities. The broad subdomain II/IV dual-targeting approach and common light chain format represent specific claim scope that may overlap with existing or planned bispecific antibody programs targeting HER2.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

ANTI-HER2 ANTIBODIES AND METHODS OF USE THEREOF

Application US20260109781A1 Kind: A1 Apr 23, 2026

Inventors

Abira BANDYOPADHYAY, Allisa Jayne CLEMENS, Do Jin KIM, Michelle E. PIZZO, Lu SHAN, Richard THÉOLIS, Jr., Raymond Ka Hang TONG

Abstract

In one aspect, antibodies that bind to subdomain II of human HER2 are provided. In another aspect, antibodies comprising a light chain polypeptide that pairs with both a heavy chain polypeptide for binding to subdomain II of human HER2 and a heavy chain polypeptide for binding to subdomain IV of human HER2 are provided. In a further aspect, antibodies that bind to both subdomain II and subdomain IV of human HER2 comprising a common light chain polypeptide are provided. Methods of treating a cancer or treating brain metastasis of a cancer using these antibodies are also provided.

CPC Classifications

C07K 16/32 A61K 35/00 A61K 45/06 A61K 2039/505 C07K 2317/31 C07K 2317/526 C07K 2317/565 C07K 2317/71 C07K 2317/72 C07K 2317/732 C07K 2317/92

Filing Date

2025-10-08

Application No.

19352786

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260109781A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Biotechnology companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Cancer treatment research Antibody therapeutics
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!